MRgFUS Pallidothalamic Tractotomy for axial symptoms in Parkinson’s disease in 4 consecutive patients: single center experience
Objective: We aimed at demonstrating the efficacy profile of MRgFUS pallidothalamic tractotomy (PTT) against the axial symptoms of Parkinson's disease. Background: Ablative neurosurgery on the…Design and Evaluation of the living lab to assess vCare system “virtual coaching activities for rehabilitation in elderly” in Parkinson´s disease patients
Objective: To evaluate the Living Lab phase from the European Project vCare (Virtual Coaching Activities for Rehabilitation in Elderly) and the satisfaction level with vCare…Shank range of motion as a measure of gait impairment in TUG test
Objective: The purpose of this study is to evaluate the efficacy of a gyroscope-based estimation of shank range of motion (RoM) as a measure to…The potential impact of physical activity to increase serum a-klotho levels in people with Parkinson’s disease
Objective: To evaluate, summarize and discuss the available literature concerning the potential effect of physical exercise on serum a-klotho levels in people with Parkinson’s disease.…Implementing a Neuropalliative Care Curriculum for Neurology Residents Focused on Neurodegenerative Diseases
Objective: To implement a neuropalliative care curriculum for neurology residents in order to increase comfort with palliative and hospice care topics for patients with progressive…Longitudinal healthcare utilization and costs in Parkinson disease : from pre-diagnosis to 9 years
Objective: The aim of this study was to characterize attributable healthcare utilization and costs in Parkinson disease (PD) in newly diagnosed PD patients managed by…Outcome of Movement Disorders affected by Covid-19: case series from a single Movement Disorders Unit
Objective: The aim of this study is to investigate the effects of corona virus (Covid-19) infection on patients with movement disorders. Background: Since the outbreak…Data Driven Paths to Advancing Precision Medicine Strategies for Parkinson’s Disease: Critical Path for Parkinson’s Consortium
Objective: An update on the accomplishments of the Critical Path for Parkinson’s (CPP) Consortium. Background: The pharmaceutical pipeline for Parkinson’s disease (PD) is rapidly expanding. Data sharing will facilitate decision making during the development…A Milestone-based approach to monitoring disease progression in Parkinson’s disease
Objective: We used Parkinson Progression Marker Initiative (PPMI) data to assess the frequency of clinically meaningful disease milestones and examine baseline predictors of reaching these…Azathioprine immunosuppression and disease modification in Parkinson’s disease (AZA-PD): a randomised double-blind placebo-controlled phase II clinical trial
Objective: To design a clinical trial to test the concept that the immune system is integral in the progression of Parkinson’s disease (PD) and establish…
- « Previous Page
- 1
- …
- 402
- 403
- 404
- 405
- 406
- …
- 436
- Next Page »